ReviewInnere Medizin (Heidelberg, Germany)2023
[Unintentional weight loss in chronic kidney disease].
Review in Innere Medizin (Heidelberg, Germany), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 1 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
If the causes of unintended weight loss are already diverse in pre-dialysis patients, at the stage of dialysis requirement a variety of other causes are added. Both stages share a trend towards loss of appetite and nausea, whereby uremic toxins certainly do not represent the only cause. In addition, both stages involve increased catabolism and therefore a higher calorie requirement. In the dialysis stage, protein loss (more in peritoneal dialysis than in hemodialysis) and the sometimes extensive dietary restrictions (low potassium, low phosphate, fluid restriction) are added. The problem of malnutrition, especially in dialysis patients, has been increasingly recognized in recent years, and there is a trend towards improvement. Initially, the causes of weight loss were subsumed under the terms protein energy wasting (PEW), which emphasized the protein loss in dialysis, and malnutrition-inflammation-atherosclerosis (MIA) syndrome, which highlighted chronic inflammation in dialysis patients; however, a variety of other factors contribute to weight loss, which are better described by the term chronic disease-related malnutrition (C-DRM). Weight loss is the most significant factor in recognizing malnutrition, as pre-existing obesity (especially type II diabetes mellitus) often makes the recognition more difficult. In the future, the increasing use of glucagon-like peptide 1 (GLP-1) agonists for weight loss could also lead to weight loss being perceived as intentional rather than distinguishing between intentional fat loss and unintentional loss of muscle mass.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.